Harnessing immunological targets for COVID-19 immunotherapy

被引：1
作者：
Mehata, Abhishesh Kumar [1 ]
Viswanadh, Matte Kasi [1 ]
Priya, Vishnu [1 ]
Vikas [1 ]
Muthu, Madaswamy S. [1 ]
机构：
[1] Indian Inst Technol BHU, Dept Pharmaceut Engn & Technol, Varanasi 221005, Uttar Pradesh, India
来源：
FUTURE VIROLOGY | 2021年 / 16卷 / 09期
关键词：
COVID-19; cytokine storm; immunotherapy; innate immunity; novel coronavirus; NEUTRALIZING ANTIBODIES; CONVALESCENT PLASMA; IMMUNE-RESPONSES; T-CELLS; CORONAVIRUS; SARS; THERAPY; INNATE; ENTRY; RECOGNITION;
D O I：
10.2217/fvl-2021-0048
中图分类号：
Q93 [微生物学];
学科分类号：
071005 ; 100705 ;
摘要：
COVID-19 is an infectious and highly contagious disease caused by SARS-CoV-2. The immunotherapy strategy has a great potential to develop a permanent cure against COVID-19. Innate immune cells are in constant motion to scan molecular alteration to cells led by microbial infections throughout the body and helps in clearing invading viruses. Harnessing immunological targets for removing viral infection, generally based on the principle of enhancing the T-cell and protective immune responses. Currently-approved COVID-19 vaccines are mRNA encapsulated in liposomes that stimulate the host immune system to produce antibodies. Given the vital role of innate immunity, harnessing these immune responses opens up new hope for the generation of long-lasting and protective immunity against COVID-19.
引用
收藏
页码：619 / 640
页数：22
相关论文
共 143 条
  • [1] Pathogen recognition and innate immunity
    Akira, S
    Uematsu, S
    Takeuchi, O
    [J]. CELL, 2006, 124 (04) : 783 - 801
  • [2] SARS-CoV-2 Vaccines: Status Report
    Amanat, Fatima
    Krammer, Florian
    [J]. IMMUNITY, 2020, 52 (04) : 583 - 589
  • [3] The possible of immunotherapy for COVID-19: A systematic review
    AminJafari, Akram
    Ghasemi, Sorayya
    [J]. INTERNATIONAL IMMUNOPHARMACOLOGY, 2020, 83
  • [4] Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected. Interim guidance
    不详
    [J]. PEDIATRIA I MEDYCYNA RODZINNA-PAEDIATRICS AND FAMILY MEDICINE, 2020, 16 (01): : 9 - 26
  • [5] [Anonymous], 2020, CHINAS SINOPHARM LAU
  • [6] [Anonymous], 2020, MODERNAS WORK COVID
  • [7] [Anonymous], PHASE CLIN TRIAL REC
  • [8] [Anonymous], 2020, NOVEL CORONAVIRUS JN
  • [9] [Anonymous], ISRCTN - ISRCTN89951424: A phase III study to investigate a vaccine against COVID-19, DOI DOI 10.1186/ISRCTN89951424
  • [10] Th17 serum cytokines in relation to laboratory-confirmed respiratory viral infection: A pilot study
    Antalis, Emmanouil
    Spathis, Aris
    Kottaridi, Christine
    Kossyvakis, Athanasios
    Pastellas, Kalliopi
    Tsakalos, Konstantinos
    Mentis, Andreas
    Kroupis, Christos
    Tsiodras, Sotirios
    [J]. JOURNAL OF MEDICAL VIROLOGY, 2019, 91 (06) : 963 - 971
12345678910